On this episode of The Pharmcast, Heidi Youngkin shares her formula to successful launch communications for biologics.
Heidi Youngkin is a 13-year veteran from Johnson & Johnson, where she served as the Executive Global Director of Global Pharmaceutical Communications and the Global Marketing Group.
After leaving Johnson & Johnson, she became the SVP of Marketing for Inventiv Health's Patient Marketing Group, so she brings a wealth of knowledge about marketing and communication strategy.
When it costs over $2.5B dollars to develop a drug, according to the most recent Tufts study, the pressure to have a successful launch is great.
Throw in that the industry is facing tighter scrutiny on pricing and value, that the science of biologics is getting more nuanced, and that there is more competition for the patients' or prescribers' time, and the world of launch communications is getting much more complex.
To help make sense of it all, join us this week as Heidi shares her formula for successful biologic launch communication.
On this week's episode of The Pharmcast, we explore the key elements of an effective regulatory strategy and how to drive value to patient and shareholders by working with the FDA. We also cover common ways agency decisions can destroy value if not done properly.
Dr. Tim Franson and Dr. Joe Lamendola recently gave a presentation to a group of private equity and venture capital funds to outline the importance of regulatory strategy for small biopharma companies.